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Mitochondrial DNA diseases are relatively common, sometimes devastating, and transmitted exclusively
through the egg to children of carrier mothers. A study in Cell by Wang et al. (2014) adds the exciting possi-
bility of a new therapy for preventingmitochondrial disease transmission predicated on the use of polar body
genomes in mice.Mitochondria are energy generators,
present in thousands of copies per
cell, and inherited maternally. They con-
tain their own small genome in a cir-
cular chromosome that is uniquely
susceptible to pathologic mutations.
Diagnosis of mitochondrial DNA
(mtDNA) disease is often difficult given
the potential involvement of multiple tis-
sues, organs, or systems. In extreme
cases of homoplasmic mutations, when
all mtDNA is mutated, e.g., Leigh’s
Syndrome, catastrophic outcomes can
occur in affected children. The perva-
sive nature of the disease translates
into a paucity of specific clinical thera-
pies for the affected patient. However,
several approaches to prevent second-
generation transmission of mitochon-
drial DNA disease include pronuclear
and spindle transfer, both relying on
replacement of defective mitochondria
with nonpathogenic mtDNA from donor
zygotes or oocytes (Wallace and Chal-
kia, 2013).
Spindle transfer involves isolating and
transplanting meiotic metaphase chro-
mosomes from a mature oocyte into thecytoplasm of enucleated donor oocyte.
During pronuclear transfer, both male
and female pronuclei are removed from
the one-celled embryo or zygote and
transferred to the cytoplasm of donor
zygote. Efforts began in the United
Kingdom in 2005 with Human Fertiliza-
tion and Embryology Authority approval
of pronuclear transfer experimenta-
tion using clinically discarded zygotes.
Subsequently, pronuclear transfer was
reported with minimal (<2%) cotransfer
of mtDNA (Craven et al., 2010). An alter-
native approach involving the use of
spindle transfer has since been champ-
ioned because it involves manipulation
of oocytes, not zygotes, with efficacy
and safety demonstrated in monkeys by
live births, normal growth curves, and
maintained low levels of carryover mtDNA
from spindle donors (Lee et al., 2012;
Tachibana et al., 2009). Additionally,
spindle transfer in human oocytes from
donors with different mtDNA genotypes
supported fertilization, embryo develop-
ment, and stem cell isolation, all with
low mitochondrial carryover (Tachibana
et al., 2013).In a recent Cell paper, Wang et al.
(2014) directly compare pronuclear and
spindle transfer outcomes in mice and
demonstrate that the latter is associated
with a significant mtDNA carryover
(over 20%) in live offspring. The authors
further explored whether polar bodies
extruded during meiosis could be used
in the context of mtDNA replacement
(Figure 1A). Wang et al. reasoned that
the genetic material present in these
polar bodies could be recovered if these
structures were harvested in a timely
manner and transferred into enucleated
oocytes or zygotes. Their initial focus
was on the first polar body that was
used to replace a sister spindle in
metaphase II oocytes (Figure 1B). Polar
bodies were transferred into enucleated
oocytes from a mouse strain carrying
a different mtDNA haplotype allowing
quantitation of donor versus host
mtDNA. In an effort to double the yield
of reconstructed oocytes, the authors
carried out spindle and polar body trans-
fer from the same oocyte. Manipulated
oocytes were fertilized and mtDNA pres-
ence was subsequently quantitated in
Figure 1. Recycling Genetic Material from Polar Bodies in Mice
(A) A schematic drawing of first (PB1) and second (PB2) polar body extrusion during meiosis. The fully grown, diploid oocyte undergoes two reductive divisions
during meiosis in the process of producing one mature, haploid oocyte. Nuclear DNA is first duplicated and divided into two sister chromatids for each pair of
parental homologous chromosomes. Homologous chromosomes pair up and may exchange genetic material by recombination. The first reductive division is
accompanied by segregation of two chromosomal complements, one of which is eliminated from the egg in the first polar body during asymmetric division of
the cytoplasm. In the second reductive division, meiosis initially arrests at metaphase II (MII) until the oocyte is activated by sperm entrance. During this division,
each sister chromatid splits into two, with one being extruded into a second polar body. The female haploid complement remaining in the egg and the entered
sperm form two pronuclei that migrate centrally and fuse to set the stage for the first mitotic division.
(B) First polar body recovery and transfer into an enucleated MII oocyte.
(C) Second polar body recovery and transfer into a zygote from which the female pronucleus has been removed.
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Previewsembryos and/or pups. Starting with a
relatively low number of mitochondria
in the first polar body culminated in
near-complete mitochondrial replace-
ment in offspring, thereby demonstrating
the desirable outcome of circumvent-
ing cotransfer of potentially pathogenic
mtDNA.
The other approach tested by Wang
et al. involved transfer of the haploid
chromosomal complement from the
second polar body (Figure 1C). In this
case, second polar bodies were recov-
ered from fertilized oocytes and fused
with recipient zygotes from which the
female pronucleus had been removed.
Again, the resultant embryos and/or
pups were relatively free from carryover
of polar body mitochondria. Wang et al.further studied mtDNA segregation in
the second generation and reported that
F2 offspring from mice produced by first
polar body transfer were all homoplasmic
with no detectable mtDNA carryover.
However, heteroplasmy was observed in
the second-generation offspring derived
by second polar body transfer, spindle
transfer, and pronuclear transfer. While
the authors acknowledge that first and
second polar bodies in the mouse have
been used to produce normal offspring,
here they demonstrate for the first time
that polar body genomes are capable
of supporting normal development in
the mouse and that their recovery and
transfer into enucleated recipient oocytes
or zygotes can achieve mitochondrial
replacement.Cell MetaboSpindle transfer as employed in the
Wang et al. study, and as previously
described in monkeys and humans, has
gained creditability for circumventing
mtDNA-based disease (Wallace and
Chalkia, 2013). Although reported mtDNA
carryover levels were slightly higher than
those for polar body transfer, they re-
mained below the threshold for clinical
significance (Samuels et al., 2013). Mito-
chondrial replacement approaches as
described herein might next be evaluated
in mouse models carrying pathogenic
mtDNA mutations as a prelude to human
studies (Ross et al., 2013). Importantly,
first polar body transfer coupled with
spindle transfer carries the intriguing pos-
sibility of increasing the yield of recon-
structed oocytes. In contrast, secondlism 20, July 1, 2014 ª2014 Elsevier Inc. 7
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Previewspolar body transfer is complicated by the
need to identify pronuclear gender, which
is relatively easy in mice though more
complicated in primates.
The ultimate objective of this body of
work is to initiate human clinical trials, in
carrier women with a prior affected child,
in efforts to prevent disease transmission
in subsequent children. Since mitochon-
drial replacement involves germline gene
therapy, however, such approaches are
currently restricted. Regulatory agencies
in the United States and United Kingdom
are evaluating safety and efficacy issues
based on animal model studies such as
Wang et al., 2014 and those described
herein (Callaway, 2014); however, it re-8 Cell Metabolism 20, July 1, 2014 ª2014 Elsmains to be seen when authorization will
be forthcoming and whether polar body
transfer will be included as an approved
approach.
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One of the biggest challenges in biology is to understand how mitochondria influence aging and age-related
diseases. Chin et al. (2014) reveal how a mitochondrial metabolite (mitobolite) inhibits mitochondrial ATPase
and extends lifespan by mimicking dietary restriction in worms.The free radical theory of aging proposes
that accumulating macromolecular dam-
age due to increased reactive oxygen
species over time causes aging. As
mitochondria are believed to be the
main contributors of free radicals,
reducing mitochondrial electron transport
chain function would be expected to in-
crease lifespan. Several studies in nema-
todes, flies, and mice have corroborated
this idea by demonstrating that genetic
inhibition of several mitochondrial com-
ponents, especially those of the electron
transport chain (ETC) complexes, can
extend lifespan (Aguilaniu et al., 2005).
However, several findings in the field
have diminished the enthusiasm for the
idea that simply the inhibition of mito-
chondrial function or even free radicals
will extend lifespan in mammals. Further-
more, restricting nutrients in mammals or
flies is accompanied by enhancement
of mitochondrial biogenesis and function(Guarente, 2008; Zid et al., 2009). This
in principle opposes the ‘‘Warburg ef-
fect,’’ as the enhancement of mitochon-
drial function helps the organism switch
from glycolysis to oxidative metabolism,
which mediates the protective effects of
dietary restriction, such as slowing aging
and decreased cancer rates. How and
when an organism reduces mitochon-
drial function to extend lifespan, how-
ever, remains unclear. Recent work by
Jing Huang and colleagues suggests
that a mitochondrial metabolite (mito-
bolite) extends lifespan by inhibition of
mitochondrial ATPase through mecha-
nisms overlapping with dietary restriction
in Caenorhabditis elegans (Chin et al.,
2014).
Mitochondrial tricarboxylic acid cycle
(TCA) metabolites, such as pyruvate,
fumarate, malate, and oxaloacetate,
have been previously shown to extend
lifespan upon feeding in C. elegans (Mou-chiroud et al., 2011; Williams et al., 2009),
though the mechanistic underpinnings
of the prolongevity effects remain to be
delineated. Chin et al. now add a-ketoglu-
tarate (KG) to the list of ‘‘youthful’’ TCA
intermediates. Using a novel, unbiased
technique, DARTS (drug affinity respon-
sive target stability), they identify the bind-
ing proteins of KG that may explain its
effects on aging. In this assay, cell lysates
were incubated in varying concentrations
of KG, followed by a complete proteoly-
sis by a mixture of proteases, with the
assumption that if KG is binding to a
protein, that protein or the associated
fragment will be protected from protease
action. Uncleaved fragments were sepa-
rated on a gel and further identified
by liquid chromatography-tandem mass
spectrometry. Chin et al. found that KG
binds to several proteins, including two
subunits of mitochondrial ATPase. Using
several biochemical assays, including
